SymBio Pharmaceuticals Limited (SYMQY)
OTCMKTS · Delayed Price · Currency is USD
1.194
0.00 (0.00%)
Jul 15, 2025, 4:00 PM EDT
SymBio Pharmaceuticals Revenue
SymBio Pharmaceuticals had revenue of 264.02M JPY in the quarter ending March 31, 2025, a decrease of -55.78%. This brings the company's revenue in the last twelve months to 2.12B, down -54.35% year-over-year. In the year 2024, SymBio Pharmaceuticals had annual revenue of 2.45B, down -56.13%.
Revenue (ttm)
2.12B JPY
Revenue Growth
-54.35%
P/S Ratio
3.98
Revenue / Employee
19.62M JPY
Employees
108
Market Cap
56.27M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.45B | -3.14B | -56.13% |
Dec 31, 2023 | 5.59B | -4.42B | -44.15% |
Dec 31, 2022 | 10.01B | 1.75B | 21.21% |
Dec 31, 2021 | 8.26B | 5.27B | 176.42% |
Dec 31, 2020 | 2.99B | 149.30M | 5.26% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |